Arbutus Biopharma

Arbutus Biopharma Corp. is a biopharmaceutical company. It engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Arbutus Biopharma advances promising drug candidates and secures financial stability

Arbutus Biopharma showcased progress in its drug development pipeline, particularly with positive Phase IIa trial results for AB-729 and the introduction of AB-343 as a promising oral coronavirus drug candidate. The company's financial stability and strategic focus on upcoming milestones position it well for future growth.

Arbutus Biopharma advances HBV and COVID-19 treatments with strong finances

Arbutus Biopharma is making significant progress in developing treatments for HBV and COVID-19, supported by a strong financial position.
While facing challenges such as FDA clinical holds and trial planning, the company is well-positioned to capitalize on upcoming opportunities.
Strategic focus on clinical advancements, financial stability, and future growth opportunities defines Arbutus Biopharma's outlook for 2023.

Arbutus Biopharma advances Hepatitis B cure development amid financial strength

Arbutus Biopharma is progressing well in its quest for a functional cure for chronic Hepatitis B, supported by a strong pipeline and financial stability.
The company faces challenges in navigating development hurdles and competition but has opportunities to lead in innovative therapies for HBV and COVID-19.
By focusing on key milestones, strategic trial designs, and effective resource management, Arbutus aims to drive growth and success in the biopharmaceutical sector.

Arbutus Biopharma focuses on HBV cure amid leadership transition

Arbutus Biopharma's strategic focus on developing a functional cure for chronic HBV and maintaining financial stability through 2026 positions the company for future growth.
While workforce reduction and legal challenges present hurdles, the company's pipeline progress and leadership transition signal resilience and adaptability.
Opportunities in pipeline expansion, partnerships, and clinical trial advancements underscore Arbutus Biopharma's potential for long-term success in the biopharmaceutical industry.

Arbutus Biopharma focuses on HBV cure, extends cash runway

Arbutus Biopharma's Q4 2023 earnings call highlighted a strategic focus on HBV and extending cash runway. Progress in clinical trials and ongoing litigation efforts against key players. Anticipating reduced cash burn in 2024 for financial sustainability.

Arbutus Biopharma reports strong financials and progresses HBV treatment pipeline

Arbutus Biopharma showcased a strong financial position and positive results in Phase 1a study of AB-836.
The company's focus on developing a functional cure for chronic HBV and advancing pipeline assets demonstrates commitment to innovation.
While facing questions on dosing strategies and trial designs, Arbutus sees opportunities in upcoming data releases and advancing clinical studies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Altimmune

Owens & Minor

Here's what drove shares of these healthcare stocks through the roof last month.

3 Healthcare Stocks That Rocketed Higher in July

WARMINSTER, Pa., July  29, 2020  (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its second quarter financial results, conference call and webcast for Friday, August 7, 2020.  The schedule for the press release and conference call/webcast are as follows:

Arbutus to Report Second Quarter 2020 Financial Results

Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Arbutus Biopharma (ABUS) Report Negative Q2 Earnings? What You Should Know

The ruling means Moderna may have to pay royalties on its mRNA-based vaccines -- including its coronavirus candidate.

Tiny Arbutus Biopharma Wins Patent Litigation Fight with COVID-19 Vaccine Implications

Arbutus Biopharma Corp. (NASDAQ: ABUS) stock has seen an incredible rise over the past few days after the firm won a patent dispute that could have implications for coronavirus vaccine frontrunner Moderna Inc.

Moderna’s Pain Is Arbutus’s Gain in COVID-19 Patent Ruling

Arbutus Biopharma Corp. (NASDAQ: ABUS) shares jumped on Tuesday after the company reported positive data from its early stage clinical trial in patients with chronic hepatitis B virus (HBV) infection.

Why One Analyst Is Doubling Its Target After Hepatitis B Study

 Mean 60 mg HBsAg reduction of 0.99 log10 IU/mL at week 12, with normal ALT and AST values throughout the follow-up period

Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729 Demonstrating a Significant and Continuous Reduction in HBsAg

Arbutus (ABUS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Arbutus (ABUS) Stock Might be a Great Pick

As of late, it has definitely been a great time to be an investor in Arbutus Biopharma.

Arbutus' Shares March Higher, Can It Continue?

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q1 2020 Results - Earnings Call Transcript

Arbutus Biopharma Corporation (ABUS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Arbutus Biopharma

Shares of Arbutus Biopharma (NASDAQ:ABUS) rose 12.6% in pre-market trading after the company reported Q1 results.

Arbutus Biopharma: Q1 Earnings Insights

Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know

Positive single dose AB-729 data in chronic hepatitis B subjects supports  further clinical development

Arbutus Announces Positive Preliminary Phase 1a/1b Clinical Trial Results for AB-729, a Proprietary GalNAc Delivered RNAi Compound in Development for People Living with Chronic Hepatitis B

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q4 2019 Results - Earnings Call Transcript

Arbutus Biopharma (ABUS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Arbutus expects to announce AB-729 Preliminary Phase 1a/1b Data late Q12020

Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Arbutus Biopharma (ABUS) Stock

Arbutus Biopharma Corporation's (ABUS) CEO Bill Collier on Q3 2019 Results - Earnings Call Transcript

WARMINSTER, Pa., Oct.  03, 2019  (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced its decision to discontinue the clinical development of AB-506, an oral capsid inhibitor. AB-506 was in a Phase 1a/1b clinical trial for the treatment of chronic hepatitis B (CHB).

Arbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B

WARMINSTER, Pa., Sept.  26, 2019  (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company will be participating in the following investor conferences in October 2019:

Arbutus to Participate in Upcoming Investor Conferences

WARMINSTER, Pa., Aug.  20, 2019  (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Andrew Cheng, M.D., Ph.D., has been appointed to the Arbutus Board of Directors effective August 17, 2019.

Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors

Arbutus Biopharma Corporation (ABUS) CEO William Collier on Q2 2019 Results - Earnings Call Transcript

Arbutus (ABUS) surges on clearance for a clinical study to evaluate its RNAi agent, AB-729 as a treatment for hepatitis B virus.

Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up

Arbutus Biopharma Corporation (ABUS) CEO Mark Murray on Q1 2019 Results - Earnings Call Transcript

News for Arbutus Biopharma Stock (ABUS)